Northern Capital Management (Wisconsin)’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Northern Capital Management (Wisconsin)’s Portfolio KERX Stock Details KERX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-28,712	Closed	-$134K	–	146
2016 Q1	$134K	Sell	28,712 -450	-2%	-$1.8K	0.06%	142
2015 Q4	$147K	Sell	29,162 -363	-1%	-$1.73K	0.06%	144
2015 Q3	$104K	Buy	29,525 +8,150	+38%	+$54.6K	0.05%	148
2015 Q2	$213K	Buy	+21,375	New	+$229K	0.1%	130

Other funds holding KERX

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Capital Management (Wisconsin)'s KERX Position: Q2 2016 in Review

Northern Capital Management (Wisconsin) sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2016, closing a stake of 28,712 shares — an estimated $134K sold.

Northern Capital Management (Wisconsin) first reported a position in KERX in Q2 2015 and held it in 4 quarters. The position peaked at $213K in Q2 2015. 118 funds tracked by Wall St. Rank hold KERX as of Q2 2016.

Northern Capital Management (Wisconsin) reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2016 after selling out during the quarter.
Northern Capital Management (Wisconsin) sold 28,712 Keryx Biopharmaceuticals Inc shares in Q2 2016, an estimated $134K.
Northern Capital Management (Wisconsin) first reported a position in Keryx Biopharmaceuticals Inc in Q2 2015 and held it in 4 quarters.
Northern Capital Management (Wisconsin)'s Keryx Biopharmaceuticals Inc position peaked at $213K in Q2 2015.
118 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2016.

Based on Northern Capital Management (Wisconsin)'s 13F filing for Q2 2016, filed 27 Jul 2016.